Brainsway Ltd. ADR (BWAY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
Brainsway Ltd. ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MM Mike Masters Masters Capital Management LLC | 1.5M | $6.3M | $24.48M | $18.18M | 288.66% |
| YL Yosef Levy Y.D. More Investments Ltd. | 237,433 | $2.26M | $3.24M | $978,223.96 | 43.32% |
 Kevin Bresler TD Waterhouse Canada Inc. | 1,430 | $19,391 | $21,778.9 | $2,387.9 | 12.31% |
| BWL Basepoint Wealth LLC Basepoint Wealth LLC | 600 | $5,706 | $8,682 | $2,976 | 52.16% |
Brainsway Ltd. ADR (BWAY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Brainsway Ltd. ADR ever had a stock split?
Brainsway Ltd. ADR Profile
| Health Care Technology Industry | Healthcare Sector | Hadar Levy CEO | NASDAQ (NMS) Exchange | 10501L106 CUSIP |
| IL Country | 129 Employees | - Last Dividend | 4 Mar 2026 Last Split | 6 Oct 1999 IPO Date |
Overview
BrainsWay Ltd. is a pioneering medical technology company focused on developing and providing noninvasive neurostimulation treatments for a variety of mental health disorders. Founded in 2003 and based in Jerusalem, Israel, the company has made significant strides in offering innovative healthcare solutions not only in the United States but also on an international scale. BrainsWay is dedicated to improving the lives of individuals suffering from mental health issues through its advanced Deep Transcranial Magnetic Stimulation (dTMS) platform technology. This commitment extends to a vast clientele including doctors, hospitals, and medical centers that specialize in psychiatry.
Products and Services
BrainsWay Ltd. offers a broad spectrum of treatments for mental health disorders through its flagship Deep Transcranial Magnetic Stimulation (dTMS) platform technology. Each application of this technology targets specific conditions, providing a noninvasive alternative to traditional treatments. The range of disorders addressed includes:
- Major Depressive Disorders: A treatment designed to mitigate the symptoms of depression, offering hope for patients who have not responded well to conventional treatment methods.
- Anxious Depression: Tailored to manage the symptoms of depression accompanied by anxiety, providing a dual approach to treatment.
- Obsessive-Compulsive Disorders (OCD): Aims at reducing the severity of OCD symptoms, offering patients a path to regain control over their compulsions and obsessions.
- Smoking Addiction: Utilized as a therapeutic measure to help individuals overcome nicotine dependence and addiction, promoting healthier lifestyle choices.
- Bipolar Disorders: Addresses the extreme mood swings associated with bipolar disorder, helping to stabilize emotions.
- Post Traumatic Stress Disorders (PTSD): Offers relief for the symptoms of PTSD, aiding individuals in the coping process after traumatic events.
- Schizophrenia: Focuses on alleviating some of the cognitive and affective symptoms related to schizophrenia, potentially improving quality of life.
- Alzheimer's Disease: Explored as a treatment to possibly slow down or alleviate some of the cognitive decline associated with Alzheimer's disease.
- Autism: Investigated for its potential to improve outcomes in individuals on the autism spectrum, focusing on enhancing communication abilities and behavioral symptoms.
- Chronic Pain: A treatment option for managing chronic pain conditions, aiming to reduce pain intensity and improve daily functioning.
- Multiple Sclerosis: Applied as a part of comprehensive care in managing symptoms associated with multiple sclerosis, potentially improving mobility and quality of life.
- Post Stroke Rehabilitation: Implemented in the rehabilitation process post-stroke, focusing on restoring lost functions and accelerating recovery.
- Parkinson's Diseases: Offers a treatment avenue for managing symptoms of Parkinson's disease, such as tremors and rigidity, aiming to enhance patient autonomy.
